At the intersection of health and the climate is an urgent crisis. This crisis affects health in ways that are wide-ranging, ...

Antimicrobial resistance (AMR) is an urgent global health crisis. AMR infections cause an estimated 1.3 million deaths globally every year, and this number is only projected to rise.

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK. Just published is an OHE ...

Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.

In August 2022, President Biden signed the Inflation Reduction Act (IRA) into law. In this OHE Insight, Amanda Cole explores the expert discussions had at ISPOR US 2023.

This is part 2 of the insight series which explores how progress towards an effective pull incentive for antibiotics can be made in Europe.

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those indications. We assembled a broad ...

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during ...